At a glance

ClinicalIndex Comparison Record

Phase 1Completed· 182 enrolled

Drug / intervention

MSC1936369B +3 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00982865

NCT00982865Phase 1Completed

Compare CT.gov

A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor MSC1936369B Given Orally to Subjects With Solid Tumours

Merck KGaA, Darmstadt, Germany·interventional·Posted Sep 23, 2009·Updated Oct 23, 2018

In Brief

A Phase 1 clinical trial evaluating MSC1936369B for Solid Tumors and Cancer. Completed, enrolled 182 participants across 9 sites in 4 countries.

Detailed Summary

This is a first in man trial with a primary objective being the determination of the Maximum Tolerated dose (MTD) and the dose-limiting toxicity (DLT) in several regimens of MEK inhibitor MSC1936369B administered orally once a day, in subjects with malignant solid tumors to see how safe is treatment with MSC1936369B.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsSolid Tumors, Cancer

CountriesAustralia, Belgium, France, Netherlands

CollaboratorsMerck Serono S.A., Geneva

Timeline

Phase 1CompletedFinished

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartDec 2007

First PostedSep 2009

Primary CompletionMar 2013

Study CompletionApr 2016

TodayJul 2026

First PostedSep 23, 2009

Enrollment StartDec 31, 2007

Primary CompletionMar 31, 2013

Study CompletionApr 30, 2016

TodayJul 2, 2026

Enrollment to primary: 5.3 yearsPosted 16.8 years ago

Interventions

MSC1936369Bdrug